Have a feature idea you'd love to see implemented?
Let us know!
FBRX Forte Biosciences Inc
Price (delayed)
$4.65
Market cap
$6.79M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$18.25
Enterprise value
-$17.71M
Forte Biosciences, Inc. is a clinical stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and
Highlights
FBRX's EPS is up by 37% YoY and by 17% QoQ
FBRX's quick ratio has dropped by 71% since the previous quarter and by 44% year-on-year
The net income has contracted by 49% YoY and by 11% from the previous quarter
Key stats
What are the main financial stats of FBRX
Market
Valuations
Earnings
Shares outstanding
1.46M
Market cap
$6.79M
Enterprise value
-$17.71M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.4
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$35.76M
EBITDA
-$35.73M
Free cash flow
-$30.72M
Per share
Balance sheet
Liquidity
EPS
-$18.25
Free cash flow per share
-$16.65
Book value per share
$11.64
Revenue per share
$0
TBVPS
$14.13
Total assets
$26.08M
Total liabilities
$9.12M
Debt
$0
Equity
$16.96M
Working capital
$16.59M
Debt to equity
0
Current ratio
2.82
Quick ratio
2.69
Net debt/EBITDA
0.69
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-98.7%
Return on equity
-117.8%
Return on invested capital
N/A
Return on capital employed
-210.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FBRX stock price
How has the Forte Biosciences stock price performed over time
Intraday
1.53%
1 week
-3.73%
1 month
-16.82%
1 year
-62.8%
YTD
-77.36%
QTD
-16.82%
Financial performance
How have Forte Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$37.22M
Net income
-$35.76M
Gross margin
N/A
Net margin
N/A
The operating income has plunged by 53% YoY and by 11% from the previous quarter
The net income has contracted by 49% YoY and by 11% from the previous quarter
Growth
What is Forte Biosciences's growth rate over time
Valuation
What is Forte Biosciences stock price valuation
P/E
N/A
P/B
0.4
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
FBRX's EPS is up by 37% YoY and by 17% QoQ
The price to book (P/B) is 90% lower than the 5-year quarterly average of 4.2 and 56% lower than the last 4 quarters average of 0.9
The equity has contracted by 41% from the previous quarter and by 32% YoY
Efficiency
How efficient is Forte Biosciences business performance
FBRX's return on equity has dropped by 72% year-on-year and by 19% since the previous quarter
The company's return on assets has shrunk by 60% YoY and by 15% QoQ
Dividends
What is FBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FBRX.
Financial health
How did Forte Biosciences financials performed over time
FBRX's total assets is 186% greater than its total liabilities
The company's total liabilities has surged by 174% QoQ and by 45% YoY
FBRX's quick ratio has dropped by 71% since the previous quarter and by 44% year-on-year
Forte Biosciences's debt is 100% less than its equity
The equity has contracted by 41% from the previous quarter and by 32% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.